# Research Proposal: Adaptive Clinical Trial Design via Deep Learning-Predicted Heterogeneous Treatment Effects and Contextual Thompson Sampling

## 1. Introduction

### 1.1 Background

Clinical trials represent the cornerstone of evidence-based medicine, yet they remain extraordinarily resource-intensive, with the average cost of bringing a new drug to market exceeding $2.6 billion and timelines spanning 10-15 years. Oncology trials face particularly acute challenges due to the profound heterogeneity in patient responses to treatment. This heterogeneity stems from complex interactions between tumor genomics, patient characteristics, comorbidities, and treatment mechanisms. Despite advances in precision medicine, conventional clinical trial designs continue to employ random allocation strategies that ignore predictable differences in how individual patients respond to treatments, resulting in suboptimal patient-arm assignments and inflated sample size requirements.

The emergence of adaptive trial designs has offered partial solutions by allowing modifications to trial parameters based on accumulating data. Simultaneously, the field of causal machine learning has made significant strides in estimating heterogeneous treatment effects (HTE) from observational data. However, these two domains have evolved largely in isolation. Current adaptive designs typically rely on aggregate response rates rather than individual-level predictions, while HTE estimation methods have primarily been applied retrospectively rather than prospectively guiding patient allocation.

Recent advances in deep representation learning have demonstrated remarkable success in capturing complex patient phenotypes from multi-modal clinical data. Transformer architectures have achieved state-of-the-art performance in encoding electronic health records (EHR) and molecular profiles, with studies reporting up to 91.2% accuracy in treatment response prediction. Concurrently, doubly robust learning methods (DR-Learner) have emerged as principled approaches for causal inference that maintain validity under model misspecification. Multi-armed bandit algorithms, particularly Thompson Sampling, have proven effective for sequential decision-making under uncertainty, offering natural frameworks for balancing exploration and exploitation in adaptive allocation.

### 1.2 Research Objectives

This research proposes to develop and validate an integrated framework—**AdaptiveTrial-HTE**—that combines deep learning-based heterogeneous treatment effect prediction with contextual Thompson Sampling for adaptive patient allocation in clinical trials. Our specific objectives are:

1. **Primary Objective:** Demonstrate that HTE-informed adaptive allocation achieves a 20-40% reduction in required sample size for 80% statistical power compared to random allocation in simulated oncology trials.

2. **Secondary Objectives:**
   - Develop multi-modal patient embeddings that capture treatment-relevant heterogeneity from EHR and molecular profiles
   - Validate that the DR-Learner framework accurately estimates conditional average treatment effects (CATE) with PEHE < 0.3
   - Establish that contextual Thompson Sampling effectively leverages HTE predictions for allocation decisions
   - Compare performance against established baselines including stratified randomization and standard adaptive designs

### 1.3 Significance

This research addresses a critical gap at the intersection of causal machine learning and clinical trial methodology. Success would yield transformative benefits across multiple dimensions:

**Scientific Impact:** The framework establishes a principled methodology for integrating predictive models into trial design while maintaining statistical validity, advancing both machine learning and clinical research methodology.

**Clinical Impact:** Reduced sample sizes translate directly to faster trial completion, enabling earlier patient access to effective treatments. For oncology patients, this acceleration can be life-saving.

**Economic Impact:** A 20-40% reduction in sample size could save $50-200 million per Phase III oncology trial, fundamentally altering the economics of drug development.

**Ethical Impact:** By allocating patients to treatments where they are predicted to respond best, the framework reduces exposure to ineffective treatments, aligning with principles of beneficence in clinical research.

## 2. Methodology

### 2.1 Framework Overview

The AdaptiveTrial-HTE framework operates through a four-step causal mechanism:

$$\text{Patient Data} \xrightarrow{\text{Step 1}} \text{Embeddings} \xrightarrow{\text{Step 2}} \text{HTE Predictions} \xrightarrow{\text{Step 3}} \text{Allocation} \xrightarrow{\text{Step 4}} \text{Reduced Variance}$$

### 2.2 Step 1: Multi-Modal Patient Embedding

We employ a transformer-based architecture to encode heterogeneous patient data into dense representations. For patient $i$ with EHR features $\mathbf{x}_i^{EHR}$ and molecular profile $\mathbf{x}_i^{mol}$, the embedding is computed as:

$$\mathbf{h}_i = \text{TransformerEncoder}\left(\text{Concat}\left[\mathbf{E}^{EHR}(\mathbf{x}_i^{EHR}), \mathbf{E}^{mol}(\mathbf{x}_i^{mol})\right]\right)$$

where $\mathbf{E}^{EHR}$ and $\mathbf{E}^{mol}$ are modality-specific embedding layers. The transformer encoder uses multi-head self-attention:

$$\text{Attention}(Q, K, V) = \text{softmax}\left(\frac{QK^T}{\sqrt{d_k}}\right)V$$

The final patient embedding $\mathbf{h}_i \in \mathbb{R}^{d}$ (where $d \in [256, 512]$) captures treatment-relevant heterogeneity through pre-training on historical treatment response data.

### 2.3 Step 2: HTE Estimation via DR-Learner

We employ the Doubly Robust Learner (DR-Learner) for estimating conditional average treatment effects. For a binary treatment $T \in \{0, 1\}$ and outcome $Y$, the CATE is defined as:

$$\tau(\mathbf{h}) = \mathbb{E}[Y(1) - Y(0) | \mathbf{H} = \mathbf{h}]$$

The DR-Learner constructs pseudo-outcomes using propensity scores $e(\mathbf{h}) = P(T=1|\mathbf{H}=\mathbf{h})$ and outcome models $\mu_t(\mathbf{h}) = \mathbb{E}[Y|T=t, \mathbf{H}=\mathbf{h}]$:

$$\tilde{Y}_i^{DR} = \mu_1(\mathbf{h}_i) - \mu_0(\mathbf{h}_i) + \frac{T_i(Y_i - \mu_1(\mathbf{h}_i))}{e(\mathbf{h}_i)} - \frac{(1-T_i)(Y_i - \mu_0(\mathbf{h}_i))}{1 - e(\mathbf{h}_i)}$$

The final CATE estimator $\hat{\tau}(\mathbf{h})$ is obtained by regressing pseudo-outcomes on embeddings using a neural network:

$$\hat{\tau}(\mathbf{h}) = f_\theta(\mathbf{h})$$

where $f_\theta$ is a multi-layer perceptron with parameters $\theta$ trained to minimize:

$$\mathcal{L}_{CATE} = \frac{1}{n}\sum_{i=1}^{n}\left(\tilde{Y}_i^{DR} - f_\theta(\mathbf{h}_i)\right)^2$$

### 2.4 Step 3: Contextual Thompson Sampling Allocation

For sequential patient allocation, we employ contextual Thompson Sampling. Let $K$ denote the number of treatment arms. For each arm $k$, we maintain a posterior distribution over the expected reward given patient context:

$$r_k(\mathbf{h}) \sim \mathcal{N}\left(\hat{\mu}_k(\mathbf{h}), \sigma_k^2(\mathbf{h})\right)$$

where $\hat{\mu}_k(\mathbf{h})$ is derived from the CATE predictions and $\sigma_k^2(\mathbf{h})$ represents uncertainty.

**Allocation Algorithm:**

```
Algorithm 1: HTE-Informed Thompson Sampling Allocation
Input: Patient embedding h_i, CATE model τ̂, arm posteriors {π_k}
Output: Treatment assignment T_i

1. For each arm k ∈ {1, ..., K}:
   a. Compute predicted benefit: μ_k = τ̂_k(h_i)
   b. Sample from posterior: r_k ~ N(μ_k, σ_k²(h_i))
2. Assign patient to arm: T_i = argmax_k r_k
3. Update posterior π_{T_i} with observed outcome
4. Return T_i
```

The posterior update follows Bayesian linear regression with the embedding as features:

$$\sigma_k^{-2}(\mathbf{h}) = \sigma_0^{-2} + \mathbf{h}^T \mathbf{A}_k^{-1} \mathbf{h}$$

where $\mathbf{A}_k$ is the design matrix for arm $k$.

### 2.5 Step 4: Variance Reduction Mechanism

The efficiency gain arises from concentrating patients in arms where they are predicted to respond best. For the average treatment effect (ATE) estimator:

$$\hat{\tau}_{ATE} = \frac{1}{n_1}\sum_{i:T_i=1}Y_i - \frac{1}{n_0}\sum_{i:T_i=0}Y_i$$

Under HTE-informed allocation, the variance is reduced because:

$$\text{Var}(\hat{\tau}_{ATE}^{adaptive}) < \text{Var}(\hat{\tau}_{ATE}^{random})$$

when patients with higher predicted treatment effects are preferentially assigned to the active arm.

### 2.6 Data Collection and Preprocessing

**Primary Data Source:** MIMIC-IV database, containing de-identified EHR data from ICU patients, supplemented with synthetic oncology-specific features.

**Data Components:**
- Demographics (age, sex, ethnicity)
- Laboratory values (complete blood count, metabolic panel, tumor markers)
- Vital signs (longitudinal measurements)
- Diagnosis codes (ICD-10)
- Medication history
- Simulated molecular profiles (gene expression, mutation status)

**Preprocessing Pipeline:**
1. Missing value imputation using multiple imputation by chained equations (MICE)
2. Temporal aggregation of longitudinal features using attention-weighted pooling
3. Normalization using z-score standardization
4. Train/validation/test split: 60%/20%/20%

### 2.7 Experimental Design

**Simulation Framework:**

We conduct 1,000 simulated oncology trials under each experimental condition using the following data-generating process:

$$Y_i = \mu_0 + \tau(\mathbf{h}_i) \cdot T_i + \epsilon_i, \quad \epsilon_i \sim \mathcal{N}(0, \sigma^2)$$

where $\tau(\mathbf{h}_i)$ represents the true individual treatment effect.

**Experimental Conditions:**

| Factor | Levels |
|--------|--------|
| Effect Size (δ) | Small (0.2), Medium (0.5), Large (0.8) |
| Heterogeneity Level | Low (10%), Medium (30%), High (50%) |
| Sample Size | 100, 200, 500, 1000 patients |

**Baseline Comparisons:**
1. **Random Allocation (1:1):** Standard randomized design
2. **Stratified Randomization:** Blocking on key prognostic factors
3. **Standard Adaptive Design:** Response-adaptive randomization without HTE
4. **TrialGPT:** Recent LLM-based trial optimization approach

### 2.8 Evaluation Metrics

**Primary Metric:**
- **Sample Size Reduction:** Percentage reduction in patients required for 80% power at α=0.05

$$\text{Reduction} = \frac{n_{random} - n_{adaptive}}{n_{random}} \times 100\%$$

**Secondary Metrics:**
- **PEHE (Precision in Estimation of Heterogeneous Effects):**

$$\text{PEHE} = \sqrt{\frac{1}{n}\sum_{i=1}^{n}\left(\hat{\tau}(\mathbf{h}_i) - \tau(\mathbf{h}_i)\right)^2}$$

- **Trial Success Rate:** Proportion of trials correctly rejecting $H_0$ when treatment is effective
- **Type I Error Rate:** Proportion of false positives under null effect
- **Allocation Bias:** Deviation from target allocation ratios

### 2.9 Statistical Analysis Plan

**Primary Analysis:**
- Wilcoxon signed-rank test comparing sample sizes between methods
- One-tailed test at α=0.05
- Report median reduction with 95% confidence intervals
- Effect size: Cohen's d

**Sensitivity Analyses:**
- Varying levels of model misspecification
- Robustness to confounding strength
- Impact of pre-training data size

**Falsification Criteria:**
1. Sample size reduction < 10%
2. PEHE > 0.5
3. Trial success rate < 75%
4. Performance worse than stratified randomization

## 3. Expected Outcomes & Impact

### 3.1 Expected Results

**Primary Outcome:** We anticipate achieving 20-40% reduction in required sample size for 80% statistical power, with the magnitude of reduction scaling with the degree of treatment effect heterogeneity. Specifically:
- Low heterogeneity (10%): 15-20% reduction
- Medium heterogeneity (30%): 25-35% reduction
- High heterogeneity (50%): 35-45% reduction

**Secondary Outcomes:**
- Multi-modal embeddings achieving ≥15% lower PEHE compared to single-modal baselines
- Trial success rates maintained at ≥80% across conditions
- Type I error rates controlled at nominal α=0.05 level

### 3.2 Scientific Impact

This research establishes a novel paradigm for integrating causal machine learning with clinical trial design. The framework provides:
- Theoretical foundations for HTE-informed adaptive allocation
- Empirical validation of efficiency gains under realistic conditions
- Open-source implementation enabling reproducibility and extension

### 3.3 Clinical and Translational Impact

Successful validation would enable:
- Faster completion of oncology trials, accelerating patient access to effective treatments
- Reduced patient exposure to ineffective treatments through intelligent allocation
- A pathway toward regulatory acceptance of ML-informed trial designs

### 3.4 Economic Impact

Conservative estimates suggest potential savings of $50-200 million per Phase III oncology trial through sample size reduction. Across the pharmaceutical industry, this could translate to billions in annual savings while accelerating drug development timelines.

### 3.5 Limitations and Future Directions

**Limitations:**
- Validation limited to simulated trials; prospective validation required
- Regulatory pathway for ML-based allocation remains uncertain
- Computational requirements may limit real-time deployment

**Future Directions:**
- Extension to multi-arm trials with continuous dosing
- Integration of real-time digital biomarkers from wearable devices
- Prospective validation in partnership with clinical trial networks
- Development of regulatory guidance for ML-informed adaptive designs

This research represents a significant step toward realizing the promise of precision medicine in clinical trial design, with the potential to fundamentally transform how we develop and evaluate new therapeutics.